Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia

Summary

In this pilot study, eligible patients will be treated with 5 days of low dose daunorubicin for one cycle only. Any patient who receives treatment on this protocol will be evaluable for toxicity. Each patient will be assessed for the development of toxicity at all scheduled visits (Days 1-5). Following participation on this brief pharmacodynamic trial, patients can then proceed to other conventional or investigational therapies, as clinically indicated.

Timeline

Start

2016-11

Primary completion

2019-04-03

Completion

2021-07-15

Drugs

Indications